

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: SEIFARTH

In re Application of:)
WOLFGANG SEIFARTH ET AL.)
International Appl. No.: PCT/DE00/01071)
International Filing Date: April 4, 2001)
For: METHOD FOR THE SPECIFICDETECTION AND IDENTIFICATION OF RETROVIRAL NUCLEIC ACIDS/RETROVIRUSES IN A SPECIMEN)

IN RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER
35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

Box PCT
Commissioner for Patents
Washington, D.C. 20231

MAILED/RECORDED 00000055 10009705

65.00 DP

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on May 23, 2002.
(Date)

URSULA B. DAY
(Name of Registered Representative)

Ursula B. Day May 23, 2002
Signature

Date of Signature

SIR:

In response to the Notification of Missing Requirements, mailed to the undersigned on April 5, 2002, applicant herewith submits a new computer readable disk containing the "Sequence Listing", as required, and a hard copy of the "Sequence Listing". Also enclosed is a statement confirming that the contents of the paper or compact disc and the computer readable form are the same and,

where applicable, include no new matter.

The Notice also sets forth that the oath or declaration by the inventor(s) must be filed together with the applicable surcharge. The undersigned points out that the proper declaration was submitted accompanied by the applicable surcharge on November 28, 2001.

A check in the amount of \$65.00 is enclosed to cover the fee for filing a substitute computer readable form.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.

Respectfully submitted,

By: Ursula B. Day
Ursula B. Day
Attorney for Applicant
Reg. No: 47,296

Date: May 23, 2002
350 Fifth Avenue
Suite 3220
New York, N.Y. 10118
(212) 244-5500
UBD:be



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
[www.uspto.gov](http://uspto.gov)


U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/009,705	Wolfgang Seifartha	SEIFARTH
INTERNATIONAL APPLICATION NO.		
PCT/DE00/01071		
LA. FILING DATE	PRIORITY DATE	
04/04/2000	05/08/1999	
CONFIRMATION NO. 4008		
371 FORMALITIES LETTER		
 *OC000000007784681*		

Date Mailed: 04/05/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Preliminary Amendments
- Request for Immediate Examination



The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$65 Surcharge for providing the oath or declaration later than the appropriate 30 months months from the priority date (37 CFR 1.492(e)) is required.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN

ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$65** for a Small Entity:

- **\$65** Late oath or declaration Surcharge.
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

TAMALA D HOLLAND

Telephone: (703) 305-5483

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/009,705	PCT/DE00/01071	SEIFARTH

Dr. Ulrike Rudolph

Patentanwältin
European Patent & Trademark Attorney

06203-61348
Fax 06203-64196

Verification Statement

We confirm that the material on the diskette submitted herewith is identical in substance to the Sequence Listing included in the description of the application entitled "Verfahren zum spezifischen Nachweis und zur Identifizierung retroviraler Nukleinsäuren / Retroviren in einem Untersuchungsgut" based on DE 199 21 419.0-44

Schriesheim, April 3, 2000

Dr. Ulrike Rudolph

Dr. Ulrike Rudolph